Your selection
Research, Innovation, Patient care, Education / 18.09.2025
Talk in the Cube: IP STRATEGIES IN BIOTECHNOLOGY
We are excited to continue the Talks in the Cube with an expert discussion focused on Strategies for Intellectual Property Rights in Biotechnology.
Effective strategies for Intellectual Property (IP) in Biotechnology include using patents for new processes and products, applying trade secrets for complex bioengineering methods, and employing trademarks for branding. A comprehensive strategy also means building adequate patent portfolios through patent jungles or "Biobetters", monitoring and defending IP rights against infringement, and potentially using licensing agreements for technology transfer.
Our two esteemed experts who are trained natural scientists AND European Patent Attorneys. They will share their insights and experiences with us.
A Panel Discussion with
Dr. Sun Jin Lee, European Patent Attorney, European Patent Litigator (UPC), Maiwald GmbH, Munich
Dr. Oliver Ladendorf, LL.B., European Patent Attorney, Kraus & Lederer PartGmbH, Munich
Dr. Uwe Lohmeier, Berlin BioScience Academy (BBA), Campus Berlin Buch GmbH (Moderation).
Topics planned to be addressed
- Smart patenting for Biotech: Portfolios providing leverage and attracting investors
- Licensing of innovative technologies: Patents for organoids and CRISPR/Cas
- Biotech Patents and AI: Examples to influence innovations and to protect data-driven discoveries.
The talk will be followed by a networking event where you can socialize over snacks and drinks.
Target audience
Founders & scientists from start-ups, small and medium-sized life science companies and scientific institutions.
Costs
Participation is free of charge. Registration is requested.
When
Thursday, 18 September 2025
5:00 p.m. - 7:00 p.m.
Where
BerlinBioCube (Building D95), Campus Berlin-Buch, Robert-Rössle-Straße 10, 13125 Berlin
Quelle: BerlinBioscience Academy
Further information and registration
Overview News
News Buch Berlin
Why APOE4 raises Alzheimer’s risk
Researchers at the Max Delbrück Center and Aarhus University have found a mechanism through which the gene variant APOE4, long linked to a high risk of developing Alzheimer’s disease, impairs neuronal...
more ...A potential new drug for stiff hearts
Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In “Cardiovascular Research,” hi...
more ...Volker Haucke receives the Ernst Schering Prize 2025
The Ernst Schering Prize 2025, endowed with 50.000 euros, is awarded to Prof. Dr. Volker Haucke, Director at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and Professor of Molecula...
more ...Events Buch Berlin
30.10.2025, 17:00
Talk im Cube: CROs IN DIAGNOSTICS AND THERAPEUTICS DEVELOPMENT
We continue the Talks in the Cube with another expert discussion – the last event for 2025 focusses on Strategies to optimize the cooperation between the sponsor and Contract Research Organizations (C...
more ...04.11.2025, 16:00
Kryo-Elektronenmikroskopie: Tiefgekühlte Proben ermöglichen das Verständnis biologischer Mechanismen
Vorlesungsreihe: Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buch. Für Lehrkräfte, Schülerinnen und Schüler sowie Interessierte.
more ...05.11.2025, 14:00
Einladung zur Vorlesung: Neurobiologie - Forschung und neue Therapieansätze
Fortbildungsveranstaltung der Neurowissenschaftlichen Gesellschaft e.V. im Rahmen der Vorlesungsreihe: Neue Wege in der Biomedizin: Aktuelle Forschungsthemen vom Campus Berlin-Buch
more ...